RZ-358 is under clinical development by Rezolute and currently in Phase II for H...
The Chamber of Commerce lawsuit is the second to challenge the drug-price negoti...
Research on the most effective use of fentanyl test strips could be useful as ot...
The vote in favor of expanding the approval of Alzheimer's treatment Leqembi fur...
Drug companies and pharmacies have reached a $17.3 billion settlement over the o...
The FDA issued a warning to device maker iRhythm for marketing its product for “...
"It would be hard for me to convince my leadership to take that leap again so so...
The grim reality is there will never be enough trained therapists to meet the de...
Join Frank David and Ken Getz to discuss the practical factors that add risk to ...
"The patient community, all payers, all regulatory agencies, they all welcome mu...
The FDA is convening a meeting of outside experts today to consider full approva...
Updated results highlighted the ongoing benefits of a CRISPR-based medicine for ...
Follow our live blog of an FDA advisory panel's hearing on Leqembi, Eisai and Bi...
About 80% of large companies self-insure, meaning that their employee health pla...
The experts who scrutinized the manuscript for the journal before it was publish...
Like the brakes that stop cars, a molecular brake exists that can prevent semico...
